Twitter Facebook Feed
Showing posts with label Anticonvulsants. Show all posts
Showing posts with label Anticonvulsants. Show all posts

MS Pain Relief

No matter what stage of multiple sclerosis a person is in, they will experience some level of pain. As the disease progresses some form of MS pain relief is going to be needed as that pain levels can become quite acute. Unfortunately for most people the standard over the counter NSAIDs have little to no effect on their pain and most physicians end up prescribing a range of anticonvulsants and antidepressants to help lower the patient's pain levels.

About the Pain

In a recent report put together by the National MS Society it is estimated that at least 50 percent of all multiple sclerosis patients suffer with some level of chronic pain. The hardest part of finding MS pain relief that works is that the disease affects everyone differently. Each person can experience different levels of pain in separate areas of their body at the same time or at different times and no two people are likely to experience the same pains.

Because multiple sclerosis is a disease that attacks the central nervous system, the pains can occur suddenly, be excruciating and then be gone just as quickly. Other pains can be chronic and last for hours or days; either type of pain needs to be dealt with as they can definitely take away from the patient's quality of life.

Treatments that Offer MS Pain Relief

Since none of the common over the counter pain medications such as aspirin, acetaminophen or ibuprofen are of any use as a form of MS pain relief, many physicians use much stronger medications. These include drugs such as Neurontin or other anticonvulsants as well as a variety of antidepressants such as Elavil. However all of these medications are known to have side effects such as weight gain, cotton mouth and in worse case scenarios have been known to cause seizures.

If the drugs can cause symptoms that are almost worse than the pain that they are supposed to be relieving, what is a person supposed to do? Most holistic practitioners will tell you that eating a healthy diet that includes seafood that is high in Omega 3 fatty acids and plenty of green vegetables combined with plenty of exercise at a level the patient can manage will help significantly with MS pain relief.

One of the latest treatments being tried is Botox. This product is used to reduce wrinkles by temporarily paralyzing muscles and nerves. Recent research is showing that the same paralysis of the nerves can help with MS pain relief; however it has not yet been approved by the FDA for widespread use.

I have benefited greatly from a book which has examined the link between what we eat and multiple sclerosis. If you would like to know what foods are attacking your body, what supplements you must take and how to create the energy that you need, then this book is a must read.

I am not a doctor nor am I qualified in medicine in any way. These are things that have worked for me in controlling my MS. Before undertaking any diet or fitness regime you should always consult your physician first.

Relieving Pain

Current Thoughts on Drug Treatments For Neuropathic Pain

Neuropathic pain results from damage to or dysfunction in the nervous system, triggered by trauma, infections and nervous system disorders. This type of pain is difficult to treat and often requires a combination of pharmacological therapies, psychological counseling and the use of some form of alternative and complementary medicine. In 2007, a study cited in the Journal of Pain estimated that 170 to 270 million people around the world suffer from peripheral neuropathy (e.g., phantom limb syndrome and complex regional pain syndrome) and neuropathic pain.

Neuropathic pain can be described as numbing or burning, plus sensations of tingling, electric shock, crawling, itching, or shooting. Excruciating pain can be caused by even the lightest touch. Mild pain stimuli are perceived as very painful. Pain on one side of the body is also felt on the other side. The area of pain increases to include larger and larger areas of the body.

Common Drug Treatments for Neuropathic Pain

o Antidepressants

Several types of antidepressants have analgesic effects (e.g., SSRI's, SNRI's, and TCA's) and can alleviate pain, but only one, duloxetine, has been approved for pain treatment by the Federal Drug Administration.

o Anticonvulsants

Several anticonvulsants (e.g., gabapentin, pregabalin) are used as standard treatment choices for neuropathic pain, even without definitive studies and in spite of such side effects as dizziness, sleep problems, or fatigue.

o Topical Medications

Topical medications (e.g., capsaicin - the pungent ingredient in hot chili -- and lidocaine) work on a small local area of the body, so they do not usually cause systemic side effects and rarely any interaction effects with other drugs. However, if the pain extends to a wider area of the body, topical treatment would not be as effective.

o Opioid

Studies have shown that opioids (e.g., oxydodone and morphine) do alleviate the pain in different neuropathic pain conditions. Common side effects of opioids include sedation, nausea, vomiting, dizziness, and respiratory depression. The long term use of opioids can also lead to physical dependency which should not be confused with physical addiction. Patients who are taking opioids to alleviate pain, if they have a prior history of drug addiction, sometimes find themselves triggered back into their addiction. Those who do not have a history of drug addiction do not first develop such an addiction from being treated with opioids.

o Other Medications

Additional medications often used to treat neuropathic pain include muscle relaxants, antispasmodics, anxiolytics (anti-anxiety, tranquilizers), sedatives-hypnotics, and psychostimulants. Current clinical trials of cannabis-based drugs (drugs containing a substance found in marijuana) indicate potential to alleviate neuopathic pain.

Continuum of Treatments for Neuropathic Pain

In 1990, The World Health Organization established guidelines for the treatment of malignant pain. This approach recommends beginning with the least invasive and the most easily manageable treatments first before attempting more invasive interventions such as pharmaceuticals, neurostimulation or opioid delivery through a reservoir or pump implanted directly inside the patient's body.

o Exercise
o Meditation and relaxation
o Over-the-counter medications
o Prescribed medications
o Physical rehabilitation
o Cognitive and behavioral therapies
o Oral opioid medications
o Nerve blocking
o Spinal cord stimulation
o Intraspinally administered opioids
o Tissue destruction procedures

Complementary and Alternative Treatments for Neuropathic Pain

Many methods considered complementary and alternative healing modalities are not mentioned in the above list. Treatments that may have profound healing and pain relieving possibilities include the following.

o Mind-body awareness, mindfulness, guided imagery and visualization
o Breath work
o Body therapy (e.g., massage, acupressure, acupuncture, Therapeutic Touch, etc.)
o Somatic Body Psychotheapy
o Expressive arts and movement therapies
o Diet and herbs and homeopathic remedies
o Aromatherapy

If you are currently suffering from neuropathic pain or chronic pain from another cause, it may be worth your while to at least check out some of the methods listed above before subjecting your body to more invasive treatments.

Anticonvulsants Market to 2016

Various anticoagulants, both branded and off-label are being used for the treatment of many indications such as epilepsy, fibroblast, migraine, osteopathic pain, bipolar disorder and anxiety. The patents of leading anticoagulants such as Topmast (respirator), Trilateral (oxcarbazepine), Departed (divalent sodium), Kepler (levetiracetam), Lamictal (lamotrigine) and Tegretol (carbamazepine) expired in 2007-2008. The wide applicability of the anticonvulsants for management of the various indications has caused the emergence of generics for these anticonvulsants in the market. This generic erosion will cause decline in the anticonvulsant market in the future.

Two anticonvulsants, Fosphenytoin and Stedesa have been filed in the US with FDA and 44% of the total anticonvulsants product pipeline is in Phase III clinical studies. The majority of these molecules are being studied as monotherapies for the treatment of epilepsy.The expected launch of these new anticonvusants in the future is expected to to stabilize the declining anticonvulsant market.

Lyrica (prefabbing) is the branded conversant product of Pfizer. Lyrica is indicated for the treatment of the epilepsy, fibroblast and osteopathic pain. Lyrica along with Neuron tin (parenting) is the first line of therapy for the treatment of osteopathic pain, especially when tricycle antidepressants are contraindicated. Lyrica is the only anticoagulant which has been approved for the treatment of fibroblast. Lyrica generated revenue of $2.57 billion and $2.84 billion for Pfizer, in 2008 and 2009 respectively.

GBI Research, the leading business intelligence provider, has released its latest research, "Anticoagulants Market to 2016 - Cost Advantage and Dosage Convenience Provided by Generic Anticoagulants Will Limit Commercial Opportunities for Novel Therapies", which provides insights into global anticoagulant market and market forecast until 2016.

Report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

The report provides an in-depth analysis of the top five therapeutic indications for which often anticoagulants are prescribed which includes epilepsy, fibroblast, migraine, osteopathic pain and bipolar disorder. The report also examines the Global anticoagulant treatment usage patterns for the covered indication. In addition, the report also includes insights into the anticoagulant R&D pipeline.

Anticonvulsants Market to 2016

Anticonvulsants Market to 2016
Various anticonvulsants, both branded and off-label are being used for the treatment of many indications such as epilepsy, fibromyalgia, migraine, neuropathic pain, bipolar disorder and anxiety. The patents of leading anticonvulsants such as Topamax (topiramate), Trileptal (oxcarbazepine), Depakote (divalproex sodium), Keppra (levetiracetam), Lamictal (lamotrigine) and Tegretol (carbamazepine) expired in 2007-2008. The wide applicability of the anticonvulsants for management of the various indications has caused the emergence of generics for these anticonvulsants in the market. This generic erosion will cause decline in the anticonvulsant market in the future.

Two anticonvulsants, Fosphenytoin and Stedesa have been filed in the US with FDA and 44% of the total anticonvulsants product pipeline is in Phase III clinical studies. The majority of these molecules are being studied as monotherapies for the treatment of epilepsy.The expected launch of these new anticonvusants in the future is expected to to stabilize the declining anticonvulsant market.

Lyrica (pregabalin) is the branded anriconvulsant product of Pfizer. Lyrica is indicated for the treatment of the epilepsy, fibromyalgia and neuropathic pain. Lyrica along with Neurontin (gabapentin) is the first line of therapy for the treatment of neuropathic pain, especially when tricyclic antidepressants are contraindicated. Lyrica is the only anticonvulsant which has been approved for the treatment of fibromyalgia. Lyrica generated revenue of $2.57 billion and $2.84 billion for Pfizer, in 2008 and 2009 respectively.

GBI Research, the leading business intelligence provider, has released its latest research, "Anticonvulsants Market to 2016 - Cost Advantage and Dosage Convenience Provided by Generic Anticonvulsants Will Limit Commercial Opportunities for Novel Therapies", which provides insights into global anticonvulsant market and market forecast until 2016.

Report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

The report provides an in-depth analysis of the top five therapeutic indications for which often anticonvulsants are prescribed which includes epilepsy, fibromyalgia, migraine, neuropathic pain and bipolar disorder. The report also examines the Global anticonvulsant treatment usage patterns for the covered indication. In addition, the report also includes insights into the anticonvulsant R&D pipeline.